Bevacizumab improves BCVA and central macular thickness in CSME patients

Article

Multiple injections of bevacizumab improve best-corrected visual acuity (BCVA) and central macular thickness in patients with persistant clinically significant macular oedema (CSME)

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

© 2025 MJH Life Sciences

All rights reserved.